IBI3046 / Innovent Biologics - LARVOL DELTA

A Study of IBI3046 in Participants With Overweight or Obesity (clinicaltrials.gov) - P1 | N=128 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

New P1 trial • Genetic Disorders • Obesity

IBI3046, an INHBE siRNA, Enables High Quality and Long-Lasting Weight Control in Preclinical Study (ADA 2026) - "1. IBI3046 is a potent and durable RNAi therapeutic agent capable of silencing hepatic INHBE mRNA expression in mice. 2."

Preclinical • Metabolic Disorders • Obesity

ADA Reference: IBI3046, an INHBE siRNA, Enables High Quality and Long-Lasting Weight Control in Preclinical Study (Abstract No.: 2662-P) (PRNewswire) - "IBI3046 demonstrated potent and durable mRNA knockdown in hINHBE KI mouse model. In the efficacy study, IBI3046 resulted in a 13% reduction in body weight and a 50% decrease in fat mass relative to control. In combination therapy, IBI3046 administered with a low dose of GLP-1RA achieved 20% body weight loss and a 80% reduction in fat mass. Combining IBI3046 with GLP-1RAs may synergistically enhance fat loss while mitigating key limitations of current anti-obesity regimens. In addition, IBI3046 extended the duration of suppressed weight regain following drug withdraw."

Preclinical • Obesity

Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions (PRNewswire) - "'The multiple oral presentations of mazdutide, across adults with type 2 diabetes and obesity, adults with obesity and adolescents with obesity, further highlight its differentiated profile as a GCG/GLP‑1 dual receptor agonist in terms of weight loss, glycemic control and metabolic benefits. In addition, the data on IBI3032 (oral daily GLP-1 small molecule), IBI3042 (oral weekly GLP-1 small molecule), IBI3040 (amylin) and IBI3046 (INHBE siRNA) represent key milestones of our next‑generation obesity pipeline with global potential...'"

Clinical data • P3 data • Preclinical • Obesity • Type 2 Diabetes Mellitus